Letters Reform of Cancer Drugs Fund

Cancer Drugs Fund: the bigger picture

BMJ 2016; 355 doi: http://dx.doi.org/10.1136/bmj.i5644 (Published 26 October 2016) Cite this as: BMJ 2016;355:i5644
  1. Carole M Longson, centre director,
  2. Linda J Landells, associate director,
  3. Elisabeth George, associate director,
  4. Meindert Boysen, programme director,
  5. Andrew Dillon, chief executive
  1. National Institute for Health and Care Excellence, Manchester M1 4BT, UK
  1. carole.longson{at}nice.org.uk

We welcome the authors’ creative ideas on the appraisal of cancer drugs.1 But they are wrong to imply that the Cancer Drugs Fund exists only to support observational data collection.2

With the drug industry playing its part through fair pricing, patients can access NICE recommended treatments up to 8 …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe